GIST-话题@MedSci

#GIST#

122篇内容 | 1363人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1455202, encodeId=f7d414552029b, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：单项自评健康测量来确定老年癌症患者相关研究, objectType=article, longId=729479, objectId=6446e2947975, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6446e2947975, replyNumber=0, likeNumber=38, createdTime=2022-06-15, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6446e2947975, moduleTitle=Oncologist：单项自评健康测量来确定老年癌症患者相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6446e2947975)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455201, encodeId=96d41455201a1, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, objectType=article, longId=301447, objectId=d0c230144eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c230144eb9, replyNumber=0, likeNumber=29, createdTime=2022-03-24, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c230144eb9, moduleTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c230144eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455200, encodeId=728b145520035, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=26, createdTime=2022-03-21, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455199, encodeId=051014551994d, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, objectType=article, longId=301132, objectId=c2d23011325d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d23011325d, replyNumber=0, likeNumber=33, createdTime=2022-03-20, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d23011325d, moduleTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d23011325d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=31, createdTime=2022-03-16, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455197, encodeId=9e19145519e75, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响, objectType=article, longId=300759, objectId=07ff300e59d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ff300e59d0, replyNumber=0, likeNumber=32, createdTime=2022-03-16, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ff300e59d0, moduleTitle=Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ff300e59d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455195, encodeId=203e1455195be, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=36, createdTime=2022-03-15, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455196, encodeId=cd96145519610, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, objectType=article, longId=300702, objectId=67e2300e0251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e2300e0251, replyNumber=0, likeNumber=39, createdTime=2022-03-15, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e2300e0251, moduleTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e2300e0251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455192, encodeId=96b61455192b9, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, objectType=article, longId=299456, objectId=55f52994568e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f52994568e, replyNumber=0, likeNumber=34, createdTime=2022-02-24, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f52994568e, moduleTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55f52994568e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455194, encodeId=67d414551949f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=35, createdTime=2022-02-24, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455191, encodeId=a8851455191b6, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, objectType=article, longId=299383, objectId=8ef92993836d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef92993836d, replyNumber=0, likeNumber=38, createdTime=2022-02-23, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef92993836d, moduleTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ef92993836d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455193, encodeId=c1dc145519312, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, objectType=article, longId=299377, objectId=94492993e786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94492993e786, replyNumber=0, likeNumber=46, createdTime=2022-02-23, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94492993e786, moduleTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94492993e786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455190, encodeId=f0aa145519016, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=47, createdTime=2021-12-02, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455189, encodeId=a1eb145518908, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, objectType=article, longId=221378, objectId=de1e2213e8db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e2213e8db, replyNumber=0, likeNumber=38, createdTime=2021-12-02, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e2213e8db, moduleTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de1e2213e8db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455188, encodeId=6be614551887c, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, objectType=article, longId=221323, objectId=976a22132323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976a22132323, replyNumber=0, likeNumber=36, createdTime=2021-12-01, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976a22132323, moduleTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976a22132323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455187, encodeId=08bd145518ed3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=35, createdTime=2021-12-01, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455186, encodeId=50001455186b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=35, createdTime=2021-12-01, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455185, encodeId=2e93145518568, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, objectType=article, longId=219184, objectId=9df12191846b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df12191846b, replyNumber=0, likeNumber=38, createdTime=2021-10-26, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df12191846b, moduleTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df12191846b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455184, encodeId=e512145518479, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, objectType=article, longId=219179, objectId=3d182191e9b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d182191e9b7, replyNumber=0, likeNumber=46, createdTime=2021-10-26, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d182191e9b7, moduleTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d182191e9b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455183, encodeId=84c7145518314, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, objectTitle=Clin Cancer Res: KIT外显子9突变的GIST患者接受辅助伊马替尼治疗的疗效：欧洲多中心回顾性研究, objectType=article, longId=218389, objectId=dae121838997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae121838997, replyNumber=0, likeNumber=50, createdTime=2021-10-12, rootId=0, userName=july_977, userId=6e445632366, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae121838997, moduleTitle=Clin Cancer Res: KIT外显子9突变的GIST患者接受辅助伊马替尼治疗的疗效：欧洲多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae121838997)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GIST

2020-05-29

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：单项自评健康测量来确定老年癌症患者相关研究

2022-06-15

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益

2022-03-24

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-03-21

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关

2022-03-20

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-03-16

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：真实世界评估诊断时年龄对转移性胰腺导管腺癌的治疗和预后影响

2022-03-16

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-03-15

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后

2022-03-15

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异

2022-02-24

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-02-24

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效

2022-02-23

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效

2022-02-23

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2021-12-02

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性

2021-12-02

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性

2021-12-01

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2021-12-01

july_977 (审核中...)

前往app查看评论内容

#GIST#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2021-12-01

july_977 (审核中...)

前往app查看评论内容

#GIST#

The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响

2021-10-26

july_977 (审核中...)

前往app查看评论内容

#GIST#

The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效

2021-10-26

july_977 (审核中...)

前往app查看评论内容

#GIST#

Clin Cancer Res: KIT外显子9突变的GIST患者接受辅助伊马替尼治疗的疗效：欧洲多中心回顾性研究

2021-10-12

科室
- - 订阅+
  - 更多科室
工具
服务